XSpray Pharma (Sweden) Today
| XSPRAY Stock | SEK 28.70 1.20 4.01% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
XSpray Pharma is trading at 28.70 as of the 21st of March 2025, a 4.01 percent decrease since the beginning of the trading day. The stock's open price was 29.9. XSpray Pharma has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden. The company has 22.68 M outstanding shares. More on XSpray Pharma AB
Moving against XSpray Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
XSpray Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. XSpray Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding XSpray Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
XSpray Pharma AB (XSPRAY) is traded on Stockholm Exchange in Sweden and employs 26 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate XSpray Pharma's market, we take the total number of its shares issued and multiply it by XSpray Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. XSpray Pharma AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 22.68 M outstanding shares.
XSpray Pharma AB has accumulated about 192.85 M in cash with (51.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.79.
Check XSpray Pharma Probability Of Bankruptcy
Ownership AllocationXSpray Pharma AB retains a total of 22.68 Million outstanding shares. XSpray Pharma AB owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check XSpray Ownership Details
XSpray Pharma AB Risk Profiles
Although XSpray Pharma's alpha and beta are two of the key measurements used to evaluate XSpray Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.02 | |||
| Standard Deviation | 4.45 | |||
| Variance | 19.78 | |||
| Risk Adjusted Performance | (0.1) |
XSpray Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in XSpray Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
XSpray Pharma Corporate Management
Elected by the shareholders, the XSpray Pharma's board of directors comprises two types of representatives: XSpray Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XSpray. The board's role is to monitor XSpray Pharma's management team and ensure that shareholders' interests are well served. XSpray Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XSpray Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kerstin Hasselgren | Chief Officer | Profile | |
| Per Andersson | Chief Officer | Profile | |
| Charlotta Liljebris | VP RD | Profile | |
| Andreas Konar | Sr Devel | Profile | |
| Thomas Walz | Chief Officer | Profile | |
| AnnaKarin Ekberg | VP Sales | Profile | |
| Christina Hagerstrand | VP Relations | Profile |
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.